Can I read SGLT2 Inhibitors in CKD Management on EtoBox?
SGLT2 Inhibitors in CKD Management by Pablo Sánchez is a document available to read on EtoBox.
What is SGLT2 Inhibitors in CKD Management about?
This editorial discusses the role of sodium-glucose cotransporter 2 (SGLT2) inhibitors in chronic kidney disease (CKD) management. It summarizes that large cardiovascular outcome trials have demonstrated that SGLT2 inhibition causes reductions in kidney function decline in patients with type 2 diabetes and CKD. Specifically, the Canagliflozin and Renal Events in Diabetes and Nephropathy Clinical Evaluation trial showed canagliflozin substantially reduces major kidney outcomes in these patients. The suppleme
- Author
- Pablo Sánchez
- Language
- EN